Market Cap 23.65B
Revenue (ttm) 3.81B
Net Income (ttm) -644.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 318.72
Profit Margin -16.92%
Debt to Equity Ratio 0.05
Volume 189,200
Avg Vol 468,388
Day's Range N/A - N/A
Shares Out 99.25M
Stochastic %K 82%
Beta 0.35
Analysts Strong Sell
Price Target $321.39

Latest News on ONC

BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript

May 7, 2025, 2:04 PM EDT - 27 days ago

BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript


BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:24 AM EST - 3 months ago

BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript


BeiGene to Present at Upcoming Investor Conferences

Feb 25, 2025, 6:01 AM EST - 3 months ago

BeiGene to Present at Upcoming Investor Conferences


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 4 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ XBI ZYME


BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Dec 12, 2024, 7:30 PM EST - 6 months ago

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor


Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Nov 19, 2024, 7:00 AM EST - 7 months ago

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

LH


BeiGene Mourns Death of Beloved Board Member Donald Glazer

Oct 28, 2024, 6:00 AM EDT - 7 months ago

BeiGene Mourns Death of Beloved Board Member Donald Glazer